Skip to main content
. 2008 Apr 3;111(12):5477–5485. doi: 10.1182/blood-2008-01-132837

Figure 7.

Figure 7

EFS of all patients as a function of level of end-consolidation MRD. Patients who were MRD+ (> .01%) had a significantly inferior outcome, with a 5-year EFS of 43% plus or minus 7%. This effect was seen on each of the 3 therapeutic studies (see text). Prognostic significance of end-consolidation MRD in all patients enrolled on therapeutic studies.